| Extracellular | | | Serum target
(noncellular) | |
|---|
Cellular target | CD3 ( Muromonab-CD3, Otelixizumab, Teplizumab, Visilizumab) • CD4 ( Clenoliximab, Keliximab, Zanolimumab) • CD11a ( Efalizumab) • CD18 ( Erlizumab) • CD20 ( Afutuzumab, Ocrelizumab, Pascolizumab) • CD23 ( Lumiliximab) • CD40 ( Teneliximab, Toralizumab) • CD62L/L-selectin ( Aselizumab) • CD80 ( Galiximab) • CD147/Basigin ( Gavilimomab, Ziralimumab) • CD154 ( Ruplizumab)
BLyS (Belimumab) • CTLA-4 (Ipilimumab, Tremelimumab) • CAT (Bertilimumab, Lerdelimumab, Metelimumab) • Integrin (Natalizumab) • Interleukin-6 receptor (Tocilizumab) • LFA-1 (Odulimomab)
IL-2 receptor/CD25 (Basiliximab, Daclizumab, Inolimomab)
T-lymphocyte ( Zolimomab aritox) |
|---|
Unsorted | Atlizumab, Atorolimumab, Cedelizumab, Dorlimomab aritox, Dorlixizumab, Fontolizumab, Gantenerumab, Gomiliximab, Lebrilizumab, Maslimomab, Morolimumab, Pexelizumab, Reslizumab, Rovelizumab, Siplizumab, Talizumab, Telimomab aritox, Vapaliximab, Vepalimomab |
|---|
|
|---|
| |
|---|
|
|---|
| |
|---|
|
|---|